# Biotech Daily Digest — 2026-01-24

**3 items from 2 sources**

## Summary by Source

- Endpoints News: 2 items
- Fierce Biotech: 1 item


## Endpoints News

- **[F2G CEO outlines biotech's FDA resubmission plans, funding and expansion](https://endpoints.news/f2g-ceo-outlines-biotechs-fda-resubmission-plans-funding-and-expansion/)**  
  _Fri, 23 Jan 2026 16:38:10 +0000_  
  F2G plans to resubmit its antifungal to the FDA after collecting Phase 3 data this coming June, CEO Francesco Maria Lavino told Endpoints News.

 The biotech's oral candidate, called olorofim, was

- **[Sanofi's Phase 3 eczema data cloud hopes for potential immunology blockbuster](https://endpoints.news/sanofis-phase-3-eczema-data-cloud-hopes-for-potential-immunology-blockbuster/)**  
  _Fri, 23 Jan 2026 15:39:18 +0000_  
  The centerpiece of Sanofi’s immunology efforts succeeded in two more Phase 3 eczema studies in the US, the company announced Friday, setting up a possible FDA submission before the end of ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/anti-vaccine-sentiment-pushes-moderna-away-new-late-stage-infectious-disease-trials" hreflang="en">Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials</a>](https://www.fiercebiotech.com/biotech/anti-vaccine-sentiment-pushes-moderna-away-new-late-stage-infectious-disease-trials)**  
  _Jan 23, 2026 11:55am_  
  As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area.
